Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TRVI with free AI briefings, catalyst countdowns, and dilution alerts.

TRVI · Trevi Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$299.4M Cash on Hand
48.4mo Cash Runway
Follow TRVI by email Get an email when TRVI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TRVI, unsubscribe in one click. Privacy

📣 What TRVI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nalbuphine Idiopathic Pulmonary Fibrosis Phase 3 · NCT07868419 Recruiting
Nalbuphine ER Prurigo Nodularis Phase 2/3 · NCT03497975 Completed
Nalbuphine HCL ER Uremic Pruritus Phase 2/3 · NCT02143648 Completed
Nalbuphine HCl solution Nalbuphine Phase 1 · NCT04018664 Completed

Also used in these trials (approved or third-party drugs, not TRVI's own candidates): Nintedanib, Pirfenidone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TRVI holds $299.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.6M/quarter from operations, an estimated runway of 48.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRVI files for a raise →

👥 Who Owns TRVI

Insiders 20.2% Institutions (286 holders) 79.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
New Enterprise Associates 16, L.P.
10% owner
Includes shares also reported by Forest Baskett, counted once
Insider 15,074,080 10.57% 2026-05-05
Paul Edward Walker
10% owner
Insider 13,222,228 9.27% 2025-12-31
Anthony A. Jr. Florence
10% owner
Includes shares also reported by Paul Edward Walker, counted once
Insider 13,222,228 9.27% 2025-12-31
Ali Behbahani
10% owner
Includes shares also reported by Paul Edward Walker, counted once
Insider 13,222,228 9.27% 2025-12-31
Mohamad Makhzoumi
10% owner
Includes shares also reported by Paul Edward Walker, counted once
Insider 13,222,228 9.27% 2025-12-31
Scott D Sandell
10% owner
Includes shares also reported by Paul Edward Walker, counted once
Insider 13,222,228 9.27% 2025-12-31
Carmen Chang
10% owner
Includes shares also reported by Paul Edward Walker, counted once
Insider 13,222,228 9.27% 2025-12-31
FMR LLC Institution (13G, 5%+) 12,562,839 8.81% 2026-06-30
Forest Baskett
10% owner
Insider 12,273,280 8.61% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 9,779,593 6.86% 2026-09-30
Thomas Sciascia
Chief Scientific Officer · +293,000 options
Insider 221,373 0.16% 2025-03-25
Jennifer L Good
President & CEO, Director · +831,400 options
Insider 213,313 0.15% 2025-03-21

Share count 142,559,400 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TRVI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRVI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.